Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Cord plasma eye drops are a biological therapeutic derived from human umbilical cord blood plasma, used for the treatment of severe ocular surface diseases and neuropathic corneal pain (NCP). These drops contain a rich concentration of neurotrophic factors, growth factors (such as EGF, TGF-β, and NGF), and anti-inflammatory cytokines, which are significantly higher than those found in autologous serum. The therapy aims to promote corneal epithelial healing and regenerate damaged corneal nerves. Developed and utilized by the Singapore Eye Research Institute (SERI) in collaboration with the Singapore Cord Blood Bank, cord plasma eye drops are employed as a standard clinical treatment at the Singapore National Eye Centre (SNEC) for refractory cases of dry eye and other ocular surface conditions.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on cord plasma eye drops.